Meet patients who may benefit from the first and only co-crystal analgesic for acute pain1,2

Get educational resources and insights from experts at your fingertips

Co-crystallization image

A unique co-crystal that helps appropriate patients manage acute pain1

SEGLENTIS leverages 4 complementary mechanisms of analgesia in the central and peripheral pathways.1,4

Eligible patients may pay as little as $25 for SEGLENTIS

Certain rules and restrictions apply.

SEGLENTIS has convenient 12-hour dosing1

A SEGLENTIS education hub

Access more information about acute pain management and SEGLENTIS

Sign up for more
information and important updates about SEGLENTIS


SEGLENTIS contains tramadol hydrochloride, an opioid agonist, and celecoxib, a nonsteroidal anti-inflammatory drug, and is indicated for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve SEGLENTIS for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:


  1. SEGLENTIS [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; October 2021.
  2. Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2022;00:1-15. doi:10.1111/papr.13136.
  3. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep.
  4. Almansa C, Frampton CS, Vela JM, Whitelock S, Plata-Salamán CR. Co-crystals as a new approach to multimodal analgesia and the treatment of pain. J Pain Res. 2019;12:2679-2689. doi:10.2147/jpr.s208082.